As of 12:49:13 PM EST. Market Open. JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting ...

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...

InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients experiencing acute respiratory distress. The European Commission granted ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a research report released on Thursday morning,Benzinga reports. The brokerage currently has a $8.00 price ...

Shares of Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale. Tellurian shares jumped 16.3% ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on InflaRx (IFRX – Research Report) today and set a price target of $8.00.Stay ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today ...

(RTTNews) - InflaRx N.V. (IFRX), a biopharmaceutical company specializing in anti-inflammatory therapeutics, announced on Wednesday that the European Commission or EC has granted marketing ...